Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Treating social anxiety disorder: VistaGen and EverInsight collaborate in Asian markets

VistaGen and EverInsight have signed a development and commercialisation agreement for the former’s first-in-class drug for social anxiety disorder. The deal focuses on the Greater China, South Korea and Southeast Asian markets and aims to complement VistaGen’s ongoing clinical trials in the US.

Close
Close
Close

Go Top